INTENSITY THERAPEUTICS, INC. Interest Expense
INTENSITY THERAPEUTICS, INC. (INTS) reported Interest Expense of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-09
- INTENSITY THERAPEUTICS, INC. interest expense for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. interest expense for the quarter ending 2023-12-31 was -$161.00, a 100.43% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. interest expense for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. interest expense for the quarter ending 2023-06-30 was $221.78K, a 1382.58% increase year-over-year.
- INTENSITY THERAPEUTICS, INC. interest expense for fiscal 2023 was $305.00K, a 271.95% increase from fiscal 2022.
- INTENSITY THERAPEUTICS, INC. interest expense for fiscal 2022 was $82.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | -$161.00 derived: sum of 2 quarters · filed 2024-05-09 | -$161.00 derived: sum of 3 quarters · filed 2024-05-09 | $221.62K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | -$161.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$161.00 derived: sum of 2 quarters · filed 2024-03-14 | $221.62K derived: sum of 3 quarters · filed 2024-03-14 | $305.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $221.78K derived: sum of 2 quarters · filed 2023-11-13 | $305.16K 10-Q · filed 2023-11-13 | $341.90K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $221.78K 10-Q · filed 2023-08-14 | $305.16K 10-Q · filed 2023-08-14 | $341.90K derived: sum of 3 quarters · filed 2024-05-09 | $357.02K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $83.00K 10-Q · filed 2024-05-09 | $120.12K derived: sum of 2 quarters · filed 2024-05-09 | $135.25K derived: sum of 3 quarters · filed 2024-05-09 | $150.21K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $37.12K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $52.25K derived: sum of 2 quarters · filed 2024-03-14 | $67.20K derived: sum of 3 quarters · filed 2024-03-14 | $82.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $15.12K 10-Q · filed 2023-11-13 | $30.08K derived: sum of 2 quarters · filed 2023-11-13 | $44.88K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $14.96K 10-Q · filed 2023-08-14 | $29.75K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |